|
Post by ashiwi on Feb 19, 2014 8:09:17 GMT -5
finance.yahoo.com/news/mannkind-corporation-present-upcoming-conferences-130000064.htmlVALENCIA, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences. The RBC Capital Markets 2014 Global Healthcare Conference on February 25, 2014 at 11:30 AM (ET) at The New York Palace in New York, New York. Cowen and Company 34th Annual Health Care Conference on March 3, 2014 at 3:30 PM (ET) at the Boston Marriott Copley in Boston, Massachusetts. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at www.mannkindcorp.com.
|
|
|
Post by babaoriley on Feb 19, 2014 10:49:00 GMT -5
Tell you the truth, ashiwi, I hope Al skips those. So much travel, poor weather, he's no doubt stressed (not sure if he's preparing for AdCom, but probably). You've earned a rest, Al, stay home!
|
|
|
Post by ashiwi on Feb 19, 2014 12:37:43 GMT -5
Don't worry Baba, Al likes to travel with his wife and dog. I know for a fact that his dog doesn't like cold weather so there's a good chance they may stay at home in CA.
|
|
|
Post by otherottawaguy on Feb 24, 2014 10:27:35 GMT -5
From: Keith Markey
MNKD: FDA Advisory Committee Meeting Is Official Mon, Feb 24, 2014 7:09 AM PST
Keith A. Markey, Ph.D., M.B.A. kmarkey@griffinsecurities.com 212-514-7914 Stock Symbol NASDAQ: MNKD Current Price $6.02 12 mos. Target Price $12.50 Market Cap $2,129.6 mln MannKind Corp. Buy Company Update : Pharmaceuticals FDA Advisory Committee Meeting Is Official Please click here for full report, including disclosures. Notice of the FDA Endocrinologic and Metabolic Drug Advisory Committee meeting has been published in the Federal Register, which means that the date is now official, April 1 st . The meeting is scheduled to open at 8 AM and to close at 5 PM. MannKind has ample data to support its NDA. The Company has conducted numerous studies involving more than 6,500 individuals to assess all aspects of its novel insulin formulation and delivery devices. The results have been consistent - Afrezza delivers insulin in a manner closely resembling the natural release of hormone from the pancreas at mealtime. As a result, the drug improves glucose control as evidenced by reduced HbA1c levels and it does so with less risk of hypoglycemia than alternative forms of insulin therapy. One of most recent trials found that type 1 diabetics had a lower incidence of severe hypoglycemia with Afrezza than with a short-acting insulin analog regardless of the ending HbA1c levels. Another trial showed that the addition of Afrezza to oral drug regimens used by early type 2 diabetics resulted in a significant drop in HbA1c levels and to less than the American Diabetes Association's target of 7% in 38% of the subjects. Finally, the Company has demonstrated Afrezza is not associated with clinically meaningful changes in pulmonary function or with increased risks of cardiovascular disease or cancer. A partnering agreement should give Afrezza solid marketing support. MannKind is well along in discussions with established drug company's worldwide to gain experienced promotional support for its drug. Terms of the ultimate deal(s) will probably reflect the Company's desire for a sizable upfront fee to expand its manufacturing capacity in 2015 and for attractive back-end compensation based on sales. MannKind had $70.8 million of cash as of December 31st and access to another $30 million via a line of credit from its Chairman and CEO, Alfred Mann. In addition, Deerfield has agreed to provide $40 million upon FDA approval through a debt agreement. We think the risk-reward balance is quite favorable . While the FDA decision is a binary event, the Company has laid a solid foundation for approval. Accordingly, we expect MannKind's novel insulin therapy to be approved for most of the 18 million diabetics in the United States, and we are maintaining our BUY recommendation.
|
|